P-312: Effects of candesartan on left ventricular geometry and diastolic function in hypertensive patients with left ventricular hypertrophy. The VIPE study
The VIPE study was designed to assess the efficacy of candesartan on hypertensive echocardiographic left ventricular hypertrophy (LVH) at short term. In this work we report the effects of the drug on the ventricular geometric pattern and the diastolic function. 97 hypertensive patients (70% females...
Gespeichert in:
| Veröffentlicht in: | American journal of hypertension 2005-05, Vol.18 (S4), p.118A-119A |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 119A |
|---|---|
| container_issue | S4 |
| container_start_page | 118A |
| container_title | American journal of hypertension |
| container_volume | 18 |
| creator | Barrios, Vivencio Calderon, Alberto Tomas, Juan P. Ruiz, Soledad Moya, Jose L. Megias, Alicia Molinero, Luis M. Vegazo, Onofre Fernandez, Raul Asin, Enrique |
| description | The VIPE study was designed to assess the efficacy of candesartan on hypertensive echocardiographic left ventricular hypertrophy (LVH) at short term. In this work we report the effects of the drug on the ventricular geometric pattern and the diastolic function. 97 hypertensive patients (70% females (F) and 30% males (M), age 68.9±9.5 years, BMI 29.3±4.7 kg/m2) with LVH diagnosed by echo were included. LVH criteria were left ventricular mass index (LVMI) ≥134 g/m2 or ≥110 (M or F). The patients were treated with a candesartan-based regimen (8mg, 16mg, +HCTZ 12.5mg, +add-on drugs to target BP |
| doi_str_mv | 10.1016/j.amjhyper.2005.03.330 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_istex</sourceid><recordid>TN_cdi_proquest_journals_1026551538</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2712520101</sourcerecordid><originalsourceid>FETCH-LOGICAL-i668-205cd888c6c6d7246e4303c33020239789c704df0ec67c5acdb4c9077a0c129b3</originalsourceid><addsrcrecordid>eNplkMtKw0AYhQdRsFZfQQZcJ_5zT9xJqVaQ2kURcRPGycRMbZM4M1HzLj6swbpzdTbfuXAQOieQEiDycpPq3aYeOutTCiBSYCljcIAmJOckUZSKQzSBLBeJAkmO0UkIGwDgUpIJ-l4ljNArPK8qa2LAbYWNbkobtI-6wW2Dt7aK-MM20TvTb7XHr7bd2egHPHK4dDrEdusMrvrGRDcaXIN_10TbBPdhcaejG-0Bf7pY_4_bs77t6iHF69rix7vVHIfYl8MpOqr0NtizP52i9c18PVsk9w-3d7Pr-8RJmSUUhCmzLDPSyFJRLi1nwMz4AQXKcpXlRgEvK7BGKiO0KV-4yUEpDYbQ_IVN0cU-tvPte29DLDZt75uxsSBApRBEsGykkj3lQrRfRefdTvuh0P6tkIopUSyengu-WJKl4KuCsx90cH4r</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1026551538</pqid></control><display><type>article</type><title>P-312: Effects of candesartan on left ventricular geometry and diastolic function in hypertensive patients with left ventricular hypertrophy. The VIPE study</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Barrios, Vivencio ; Calderon, Alberto ; Tomas, Juan P. ; Ruiz, Soledad ; Moya, Jose L. ; Megias, Alicia ; Molinero, Luis M. ; Vegazo, Onofre ; Fernandez, Raul ; Asin, Enrique</creator><creatorcontrib>Barrios, Vivencio ; Calderon, Alberto ; Tomas, Juan P. ; Ruiz, Soledad ; Moya, Jose L. ; Megias, Alicia ; Molinero, Luis M. ; Vegazo, Onofre ; Fernandez, Raul ; Asin, Enrique</creatorcontrib><description>The VIPE study was designed to assess the efficacy of candesartan on hypertensive echocardiographic left ventricular hypertrophy (LVH) at short term. In this work we report the effects of the drug on the ventricular geometric pattern and the diastolic function. 97 hypertensive patients (70% females (F) and 30% males (M), age 68.9±9.5 years, BMI 29.3±4.7 kg/m2) with LVH diagnosed by echo were included. LVH criteria were left ventricular mass index (LVMI) ≥134 g/m2 or ≥110 (M or F). The patients were treated with a candesartan-based regimen (8mg, 16mg, +HCTZ 12.5mg, +add-on drugs to target BP <140/90) during a 6-month follow up. Blood pressure (BP): 160.4±11.8/90.4±8.7 mmHg. LVMI: 165.5±32 (M) and 144.6±30.7 g/m2 (F). Relative wall thickness (RWT): 0.46±0.08. Ventricular geometric pattern: 54% concentric LVH (cLVH), 46% eccentric LVH (eLVH). Doppler diastolic parameters: E peak velocity (E) 0.70±0.17 m/sc; A peak velocity (A) 0.87±0.23 m/sc; E/A ratio 0.78±0.21; E wave deceleration time (DT) 223.2±63.1 msc; Isovolumic relaxation time (IVRT) 114.7±21 msc. Results: At 6 months, BP lowered to 141.1±16.8/81.1±10.7 (p<0.001 vs baseline). LVMI reduced 11.3±9.3%. RWT 0.44±0.08 (p<0.05 vs baseline). Ventricular geometry: 32% cLVH, 40% eLVH, 8.5% concentric remodeling and 19.5% normal (p=0.0025 vs baseline). No significant changes were observed in diastolic parameters: E, A, E/A ratio, DT or IVRT. No significant changes were observed in ejection fraction. The drug was very well tolerated and no serious adverse events was reported. Conclusions: The LVH regression observed with a short-term treatment based on candesartan is associated with a significant improvement in ventricular geometry. In almost one fifth of the patients the left ventricular pattern was normalised at six months. No significant changes in diastolic function parameters were observed. These data may suggest that the cardioprotective effects of candesartan could be observed earlier on LVH regression than on diastolic function improvement, what maybe needs more time.</description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1941-7225</identifier><identifier>DOI: 10.1016/j.amjhyper.2005.03.330</identifier><identifier>CODEN: AJHYE6</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Angiotensin Receptor Blocker ; Diastolic Function ; Left Ventricular Hypertrophy</subject><ispartof>American journal of hypertension, 2005-05, Vol.18 (S4), p.118A-119A</ispartof><rights>Copyright Nature Publishing Group May 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Barrios, Vivencio</creatorcontrib><creatorcontrib>Calderon, Alberto</creatorcontrib><creatorcontrib>Tomas, Juan P.</creatorcontrib><creatorcontrib>Ruiz, Soledad</creatorcontrib><creatorcontrib>Moya, Jose L.</creatorcontrib><creatorcontrib>Megias, Alicia</creatorcontrib><creatorcontrib>Molinero, Luis M.</creatorcontrib><creatorcontrib>Vegazo, Onofre</creatorcontrib><creatorcontrib>Fernandez, Raul</creatorcontrib><creatorcontrib>Asin, Enrique</creatorcontrib><title>P-312: Effects of candesartan on left ventricular geometry and diastolic function in hypertensive patients with left ventricular hypertrophy. The VIPE study</title><title>American journal of hypertension</title><addtitle>AJH</addtitle><description>The VIPE study was designed to assess the efficacy of candesartan on hypertensive echocardiographic left ventricular hypertrophy (LVH) at short term. In this work we report the effects of the drug on the ventricular geometric pattern and the diastolic function. 97 hypertensive patients (70% females (F) and 30% males (M), age 68.9±9.5 years, BMI 29.3±4.7 kg/m2) with LVH diagnosed by echo were included. LVH criteria were left ventricular mass index (LVMI) ≥134 g/m2 or ≥110 (M or F). The patients were treated with a candesartan-based regimen (8mg, 16mg, +HCTZ 12.5mg, +add-on drugs to target BP <140/90) during a 6-month follow up. Blood pressure (BP): 160.4±11.8/90.4±8.7 mmHg. LVMI: 165.5±32 (M) and 144.6±30.7 g/m2 (F). Relative wall thickness (RWT): 0.46±0.08. Ventricular geometric pattern: 54% concentric LVH (cLVH), 46% eccentric LVH (eLVH). Doppler diastolic parameters: E peak velocity (E) 0.70±0.17 m/sc; A peak velocity (A) 0.87±0.23 m/sc; E/A ratio 0.78±0.21; E wave deceleration time (DT) 223.2±63.1 msc; Isovolumic relaxation time (IVRT) 114.7±21 msc. Results: At 6 months, BP lowered to 141.1±16.8/81.1±10.7 (p<0.001 vs baseline). LVMI reduced 11.3±9.3%. RWT 0.44±0.08 (p<0.05 vs baseline). Ventricular geometry: 32% cLVH, 40% eLVH, 8.5% concentric remodeling and 19.5% normal (p=0.0025 vs baseline). No significant changes were observed in diastolic parameters: E, A, E/A ratio, DT or IVRT. No significant changes were observed in ejection fraction. The drug was very well tolerated and no serious adverse events was reported. Conclusions: The LVH regression observed with a short-term treatment based on candesartan is associated with a significant improvement in ventricular geometry. In almost one fifth of the patients the left ventricular pattern was normalised at six months. No significant changes in diastolic function parameters were observed. These data may suggest that the cardioprotective effects of candesartan could be observed earlier on LVH regression than on diastolic function improvement, what maybe needs more time.</description><subject>Angiotensin Receptor Blocker</subject><subject>Diastolic Function</subject><subject>Left Ventricular Hypertrophy</subject><issn>0895-7061</issn><issn>1941-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNplkMtKw0AYhQdRsFZfQQZcJ_5zT9xJqVaQ2kURcRPGycRMbZM4M1HzLj6swbpzdTbfuXAQOieQEiDycpPq3aYeOutTCiBSYCljcIAmJOckUZSKQzSBLBeJAkmO0UkIGwDgUpIJ-l4ljNArPK8qa2LAbYWNbkobtI-6wW2Dt7aK-MM20TvTb7XHr7bd2egHPHK4dDrEdusMrvrGRDcaXIN_10TbBPdhcaejG-0Bf7pY_4_bs77t6iHF69rix7vVHIfYl8MpOqr0NtizP52i9c18PVsk9w-3d7Pr-8RJmSUUhCmzLDPSyFJRLi1nwMz4AQXKcpXlRgEvK7BGKiO0KV-4yUEpDYbQ_IVN0cU-tvPte29DLDZt75uxsSBApRBEsGykkj3lQrRfRefdTvuh0P6tkIopUSyengu-WJKl4KuCsx90cH4r</recordid><startdate>200505</startdate><enddate>200505</enddate><creator>Barrios, Vivencio</creator><creator>Calderon, Alberto</creator><creator>Tomas, Juan P.</creator><creator>Ruiz, Soledad</creator><creator>Moya, Jose L.</creator><creator>Megias, Alicia</creator><creator>Molinero, Luis M.</creator><creator>Vegazo, Onofre</creator><creator>Fernandez, Raul</creator><creator>Asin, Enrique</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>200505</creationdate><title>P-312: Effects of candesartan on left ventricular geometry and diastolic function in hypertensive patients with left ventricular hypertrophy. The VIPE study</title><author>Barrios, Vivencio ; Calderon, Alberto ; Tomas, Juan P. ; Ruiz, Soledad ; Moya, Jose L. ; Megias, Alicia ; Molinero, Luis M. ; Vegazo, Onofre ; Fernandez, Raul ; Asin, Enrique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i668-205cd888c6c6d7246e4303c33020239789c704df0ec67c5acdb4c9077a0c129b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Angiotensin Receptor Blocker</topic><topic>Diastolic Function</topic><topic>Left Ventricular Hypertrophy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barrios, Vivencio</creatorcontrib><creatorcontrib>Calderon, Alberto</creatorcontrib><creatorcontrib>Tomas, Juan P.</creatorcontrib><creatorcontrib>Ruiz, Soledad</creatorcontrib><creatorcontrib>Moya, Jose L.</creatorcontrib><creatorcontrib>Megias, Alicia</creatorcontrib><creatorcontrib>Molinero, Luis M.</creatorcontrib><creatorcontrib>Vegazo, Onofre</creatorcontrib><creatorcontrib>Fernandez, Raul</creatorcontrib><creatorcontrib>Asin, Enrique</creatorcontrib><collection>Istex</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barrios, Vivencio</au><au>Calderon, Alberto</au><au>Tomas, Juan P.</au><au>Ruiz, Soledad</au><au>Moya, Jose L.</au><au>Megias, Alicia</au><au>Molinero, Luis M.</au><au>Vegazo, Onofre</au><au>Fernandez, Raul</au><au>Asin, Enrique</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P-312: Effects of candesartan on left ventricular geometry and diastolic function in hypertensive patients with left ventricular hypertrophy. The VIPE study</atitle><jtitle>American journal of hypertension</jtitle><addtitle>AJH</addtitle><date>2005-05</date><risdate>2005</risdate><volume>18</volume><issue>S4</issue><spage>118A</spage><epage>119A</epage><pages>118A-119A</pages><issn>0895-7061</issn><eissn>1941-7225</eissn><coden>AJHYE6</coden><abstract>The VIPE study was designed to assess the efficacy of candesartan on hypertensive echocardiographic left ventricular hypertrophy (LVH) at short term. In this work we report the effects of the drug on the ventricular geometric pattern and the diastolic function. 97 hypertensive patients (70% females (F) and 30% males (M), age 68.9±9.5 years, BMI 29.3±4.7 kg/m2) with LVH diagnosed by echo were included. LVH criteria were left ventricular mass index (LVMI) ≥134 g/m2 or ≥110 (M or F). The patients were treated with a candesartan-based regimen (8mg, 16mg, +HCTZ 12.5mg, +add-on drugs to target BP <140/90) during a 6-month follow up. Blood pressure (BP): 160.4±11.8/90.4±8.7 mmHg. LVMI: 165.5±32 (M) and 144.6±30.7 g/m2 (F). Relative wall thickness (RWT): 0.46±0.08. Ventricular geometric pattern: 54% concentric LVH (cLVH), 46% eccentric LVH (eLVH). Doppler diastolic parameters: E peak velocity (E) 0.70±0.17 m/sc; A peak velocity (A) 0.87±0.23 m/sc; E/A ratio 0.78±0.21; E wave deceleration time (DT) 223.2±63.1 msc; Isovolumic relaxation time (IVRT) 114.7±21 msc. Results: At 6 months, BP lowered to 141.1±16.8/81.1±10.7 (p<0.001 vs baseline). LVMI reduced 11.3±9.3%. RWT 0.44±0.08 (p<0.05 vs baseline). Ventricular geometry: 32% cLVH, 40% eLVH, 8.5% concentric remodeling and 19.5% normal (p=0.0025 vs baseline). No significant changes were observed in diastolic parameters: E, A, E/A ratio, DT or IVRT. No significant changes were observed in ejection fraction. The drug was very well tolerated and no serious adverse events was reported. Conclusions: The LVH regression observed with a short-term treatment based on candesartan is associated with a significant improvement in ventricular geometry. In almost one fifth of the patients the left ventricular pattern was normalised at six months. No significant changes in diastolic function parameters were observed. These data may suggest that the cardioprotective effects of candesartan could be observed earlier on LVH regression than on diastolic function improvement, what maybe needs more time.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1016/j.amjhyper.2005.03.330</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0895-7061 |
| ispartof | American journal of hypertension, 2005-05, Vol.18 (S4), p.118A-119A |
| issn | 0895-7061 1941-7225 |
| language | eng |
| recordid | cdi_proquest_journals_1026551538 |
| source | Oxford University Press Journals All Titles (1996-Current) |
| subjects | Angiotensin Receptor Blocker Diastolic Function Left Ventricular Hypertrophy |
| title | P-312: Effects of candesartan on left ventricular geometry and diastolic function in hypertensive patients with left ventricular hypertrophy. The VIPE study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T00%3A06%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_istex&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P-312:%20Effects%20of%20candesartan%20on%20left%20ventricular%20geometry%20and%20diastolic%20function%20in%20hypertensive%20patients%20with%20left%20ventricular%20hypertrophy.%20The%20VIPE%20study&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Barrios,%20Vivencio&rft.date=2005-05&rft.volume=18&rft.issue=S4&rft.spage=118A&rft.epage=119A&rft.pages=118A-119A&rft.issn=0895-7061&rft.eissn=1941-7225&rft.coden=AJHYE6&rft_id=info:doi/10.1016/j.amjhyper.2005.03.330&rft_dat=%3Cproquest_istex%3E2712520101%3C/proquest_istex%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1026551538&rft_id=info:pmid/&rfr_iscdi=true |